Zobrazeno 1 - 10
of 55
pro vyhledávání: ''
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Publikováno v:
Cancer Research. 79:P5-11
Background: CDK4/6 inhibition combined with endocrine therapy is now a standard of care for advanced estrogen receptor (ER) positive breast cancer. Predictive genetic landscape and mechanisms of resistance to CDK4/6 inhibitors have not been described
Autor:
Ulivi Paola, Laura Matteucci, Milena Urbini, Alessandro Passardi, Gianluca Tedaldi, Giorgia Marisi, Matteo Canale, Giovanni Martinelli, Giovanni Luca Frassineti, Chiara Molinari
Publikováno v:
Cancer Research. 81:541-541
The use of liquid biopsy in the clinical management of colorectal cancer (CRC) patients is not yet a routine clinical practice, although it could give important information for tumor baseline characterization and for monitoring during treatment. In t
Autor:
Maura N. Dickler, A. Cervantes, Heidi Savage, T. R. Wilson, Cristina Saura, Ian E. Krop, Donald A. Richards, Marcos Vinicius Silva Oliveira, Huan Jin, Thomas J Stout, J. Baselga
Publikováno v:
Cancer Research. 77:P6-12
Background: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in hormone receptor (HR)-positive breast cancer (BC), with activating mutations of PIK3CA detected in ~35–45% of patients (pts). Acquired mutations in the ESR1
Autor:
Stephen N. Thibodeau, Michelle R. Mahoney, Richard M. Goldberg, Harry H. Yoon, Daniel J. Sargent, Thomas C. Smyrk, Steven R. Alberts, Frank A. Sinicrope, Garth D. Nelson
Publikováno v:
Clinical Cancer Research. 21:5294-5304
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (ex
Autor:
Luigi Formisano, Erika Martinelli, Matilde Lambiase, Francesca Fenizia, Roberto Bianco, Floriana Morgillo, Fortunato Ciardiello, Giulia Martini, Donata Vitagliano, Teresa Troiani, Claudia Cardone, Nicola Normanno, Davide Ciardiello, Stefania Napolitano
Publikováno v:
Clinical Cancer Research. 21:4153-4164
Purpose: The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental Design: We have investigated in three models of highly epidermal growth factor receptor (EGFR)–dependent colorectal
Autor:
Pasi A. Jänne, Christine A. Lydon, Lynette M. Sholl, Mizuki Nishino, Emily Chambers, Natalie I. Vokes, Eliezer M. Van Allen, Tom C. Nguyen
Publikováno v:
Cancer Research. 80:5882-5882
Background: Oncogenic mutations in EGFR are powerful biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, there remains significant heterogeneity in duration of response to therapy and overa
Autor:
Anne de la Rochefordière, Ivan Bièche, Virginie Fourchotte, Florence Joly, Emmanuel Sevin, Béatrice Weber, Mathieu Minsat, Benard Asselain, Anne Floquet, Maud Kamal, Suzy Scholl, Maud Aumont, Quentin Leroy, Laurence Thomas, Marius Pop, Alhassane Diallo, Sophie Maillard, Hervé Curé, Michel Fabbro, Peter Petrow, Philippe Beuzeboc, Thierry Petit, K. Peignaux, Laurence Gladieff, Corine Plancher, Laurence Gonzague, Virginie Bernard, Claire Brunaud, Christine Kerr, Dominique Berton-Rigaud, AnaTereza Nadan, Sebastien Armanet, Audrey Margogne
Publikováno v:
Clinical Cancer Research. 21:2530-2537
Purpose: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcino
Autor:
Noelia Ferruz, Israel Cañadas, Alba Dalmases, Joaquim Bellmunt, Marta Salido, Federica Di Nicolantonio, Giorgio Corti, Alberto Bardelli, Mar Iglesias, Juan Sánchez, Giovanni Crisafulli, Elena Gavilán, Sandra Misale, Alejandro Martínez, Joan Albanell, Clara Montagut, Iria Gonzalez, Gianni De Fabritiis, Beatriz Bellosillo, Mariangela Russo, Giulia Siravegna, Sabrina Arena, Ana Rovira, Sebastijan Hobor, Luca Lazzari
Publikováno v:
Clinical Cancer Research. 21:2157-2166
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascer
Autor:
Alexandra M. Ward, Marek Kimmel, Heath D. Skinner, Thomas J. Ow, Ameeta A. Patel, Thomas O. McDonald, David M. Neskey, Paolo Bossi, Teng-Kuei Hsu, Jeffrey N. Myers, Mei Zhao, Federica Perrone, Abdullah A. Osman, Panagiotis Katsonis, Adel K. El-Naggar, Marcus V. Ortega Alves, Curtis R. Pickering, Erich M. Sturgis, Stephanie C. Hicks, Merrill S. Kies, Lisa Licitra, Olivier Lichtarge, Mitchell J. Frederick
Publikováno v:
Cancer Research. 75:1205-1215
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the cu